- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Significant Interest from Japanese Pharmas in EKC Drug Candidate
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), said that the internationally renowned Japanese ophthalmologist and corneal researcher, Kazuo Tsubota, MD, PhD, has agreed to join the Company's Scientific Advisory Board. Dr. Tsubota is currently Professor and Chairman of the Department of Ophthalmology at Keio University School of Medicine in Tokyo, Japan.
"I have already had licensing discussions with Japanese pharmaceutical companies regarding EkcCide™," said Dr. Tsubota, adding, "There has been significant interest in Japan in the excellent animal study results from the Institute in New York."
"Dr. Tsubota will be helping us prepare the Company's nanoviricides drug candidates to enter the regulatory approval process in Japan. Initially, he will focus on viral eye diseases such as EKC and Herpes virus infection, among others," said Eugene Seymour, MD, MPH, CEO of the Company.
There are a number of different viruses that cause both viral conjunctivitis and keratitis (inflammation of the cornea). Adenovirus is a common cause of the very severe and potentially debilitating EKC. Herpes simplex virus (HSV-1) is another important infection of the eye. HSV-I infection is frequently recurrent and can lead to corneal scarring which may necessitate corneal transplantation.
The Company has previously reported that EkcCide was shown to cause rapid and clear clinical recovery of infected animal eyes in a study conducted by a renowned US ophthalmologic Institute. The infection in this study was caused by adenovirus 5, supplied by the Centers for Disease Control and Prevention (CDC). Representative photographs are posted on the Company's website (www.nanoviricides.com).
EkcCide is the Company's nanoviricide™ drug candidate designed against the adenovirus that causes epidemic-kerato-conjunctivitis (EKC). The Company anticipates that the eye-drop formulation of this broad-spectrum nanoviricide drug candidate may have significant potential against other viral causes of EKC, herpes infection of the eye and the less severe viral conjunctivitis diseases as well. Common viral conjunctivitis is highly contagious and occurs primarily in schools and other crowded settings, as well as in immuno-compromised populations. While the Company currently has no approved product for the treatment of EKC and viral conjunctivitis, the treatment and prophylaxis market for EKC and other viral causes of conjunctivitis is expected to be in the order of several billion dollars annually.
About Kazuo Tsubota, MD, PhD:
An internationally recognized eye specialist, Professor Tsubota is Chairman of the Department of Ophthalmology at Keio University School of Medicine, his alma mater, where he received his MD in 1980. He was the first Japanese recipient of the American Academy of Ophthalmology Honor Award in 1994. He is Chief Surgeon at the Minamiaoyama Eye Clinic in Tokyo, Japan. He heads a large dry eye research group and also the largest refractive (eye) group in Japan, which has several clinics throughout the country. He is author of more than 350 scientific peer reviewed articles. He is editor of several specialty books in ophthalmology and is also a reviewer for many international journals in ophthalmology.
About NanoViricides, Inc.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, EKC, hepatitis C, rabies, dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development efforts, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the “Management’s Discussion and Analysis” section of the Company’s Form 10-KSB and other reports and filings with the Securities and Exchange Commission.
For more information, please click here
Copyright © Business Wire 2008If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Leti Announces Launch of First European Nanomedicine Characterisation Laboratory: Project Combines Expertise of 9 Partners in 8 Countries to Foster Nanomedicine Innovation and Facilitate Regulatory Approval July 1st, 2015
Janusz Bryzek Joins MEMS Industry Group to Lead New TSensors Division - New Division will Focus on Accelerating Development of Emerging Ultra-high Volume Sensors Supporting Abundance, mHealth and IoT May 14th, 2015